Pharmacopeia, Inc.
Records under this name other than the patents Pharmacopeia, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,763,616 | Piperazine-Piperidines with CXCR3 Antagonist Activity Formerly held In force · High confidence | In force | High confidence | |
| US 7,786,124 | Novel Heterocyclic Substituted Pyridine Compounds with CXCR3 Antagonist Activity Formerly held In force · High confidence | In force | High confidence | |
| US 7,902,199 | Heterocyclic Substituted Piperazine Compounds with CXCR3 Antagonist Activity Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 7,820,649 | Quinazolinone and Isoquinolinone Acetamide Derivatives Formerly held In force · High confidence | In force | High confidence | |
| US 7,906,504 | 2-(1-OXO-1H-ISOQUINOLIN-2-YL)ACETAMIDE Derivatives Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 7,902,187 | 6-Substituted 2-(BENZIMIDAZOLYL)PURINE and Purinone Derivatives for Immunosuppression Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 7,759,353 | Substituted Spiro Iminopyrimidinones as Aspartyl Protease Inhibitors, Compositions, and Methods of Treatment Held by another company In force · High confidence | In force | High confidence | |
| US 8,314,091 | N-Benzyl,n'-Arylcarbonylpiperazine Derivatives Formerly held In force · High confidence | In force | High confidence | |
| US 8,759,352 | 1-(4-Ureidobenzoyl)PIPERAZINE Derivatives Lapsed on the fee record Ended Jun 24, 2026 · High confidence | Lapsed on the fee record | Ended Jun 24, 2026 | High confidence |
| US 7,807,686 | 2-(4-OXO-4H-QUINAZOLIN-3-YL) Acetamides and Their Use as Vasopressin V3 Antagonists Formerly held Term ended Term ended Mar 10, 2026 · High confidence | Term ended | Term ended Mar 10, 2026 | High confidence |